Altered D-Chiro-inositol urinary clearance in women with polycystic ovary syndrome

被引:125
作者
Baillargeon, JP [1 ]
Diamanti-Kandarakis, E
Ostlund, RE
Apridonidze, T
Iuorno, MJ
Nestler, JE
机构
[1] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1H 5N4, Canada
[2] Univ Athens, Sch Med, Endocrine Sect, Dept Med 1, GR-11527 Athens, Greece
[3] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[4] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA
[5] Virginia Commonwealth Univ, Dept Obstet & Gynecol, Richmond, VA 23298 USA
关键词
D O I
10.2337/diacare.29.02.06.dc05-1070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Evidence suggests that some actions of insulin are effected by inositolphosphoglycan (IPG) mediators. We hypothesize that a deficiency in D-chiro-inositol (DCI) and/or a DCI-containing IPG (DCI-IPG) may contribute to insulin resistance in humans. RESEARCH DESIGN AND METHODS - To assess this possibility in polycystic ovary syndrome (PCOS), we determined insulin sensitivity (Si by frequently sampled intravenous glucose tolerance test), plasma and urinary DCI and myo-inositol (MYO) levels (by gas chromatography/mass spectrometry), and the release of insulin and DCI-IPG during the oral glucose tolerance test (area under the curve [AUC]) in 23 women with PCOS and 26 normal women. RESULTS - Women with PCOS were heavier than control subjects (P = 0.002 for BMI), but also had decreased S-1 (P < 0.001) and increased AUC(insulin) (P < 0.001) compared with normal women, even when corrected for BMI. The urinary clearance of DCI.(uCl(DCl)) was increased almost sixfold in PCOS compared with normal women (P = 0.001), but not MYO clearance (P = 0.10) uCl(DCI), correlated inversely with S-1 when all women were analyzed together (n = 49, r = 0.50, P < 0.001) and was one of the three best independent parameters predicting S-1. Finally, the ratio of AUC(DCl-IPG) to AUC(insulin) was decreased threefold in women with PCOS (P < 0.001). CONCLUSIONS - uCl(DCI) is inversely correlated with insulin sensitivity in women and is a strong independent predictor of insulin resistance in multivariate models. PCOS, which is characterized by insulin resistance, is associated with a selective increase in uCl(DCI) and impaired DCI-IPG release in response to insulin. These findings are consistent with a defect in tissue availability or utilization of DCI in PCOS that may contribute to the insulin resistance of the syndrome.
引用
收藏
页码:300 / 305
页数:6
相关论文
共 30 条
[1]  
[Anonymous], CURRENT ISSUES ENDOC
[2]   CHIRO-INOSITOL DEFICIENCY AND INSULIN-RESISTANCE - A COMPARISON OF THE CHIRO-INOSITOL-CONTAINING AND THE MYO-INOSITOL-CONTAINING INSULIN MEDIATORS ISOLATED FROM URINE, HEMODIALYSATE, AND MUSCLE OF CONTROL AND TYPE-II DIABETIC SUBJECTS [J].
ASPLIN, I ;
GALASKO, G ;
LARNER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :5924-5928
[3]   Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome [J].
Baillargeon, JP ;
Iuorno, MJ ;
Jakubowicz, DJ ;
Apridonidze, T ;
He, N ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :242-249
[4]   Insulin sensitizers for polycystic ovary syndrome [J].
Baillargeon, JP ;
Iuorno, MJ ;
Nestler, JE .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2003, 46 (02) :325-340
[5]  
BAILLARGEON JP, 2002, CURR OPIN ENDOCRINOL, V9, P303
[6]   TOWARD PHYSIOLOGICAL UNDERSTANDING OF GLUCOSE-TOLERANCE - MINIMAL-MODEL APPROACH [J].
BERGMAN, RN .
DIABETES, 1989, 38 (12) :1512-1527
[7]   PHYSIOLOGIC EVALUATION OF FACTORS CONTROLLING GLUCOSE-TOLERANCE IN MAN - MEASUREMENT OF INSULIN SENSITIVITY AND BETA-CELL GLUCOSE SENSITIVITY FROM THE RESPONSE TO INTRAVENOUS GLUCOSE [J].
BERGMAN, RN ;
PHILLIPS, LS ;
COBELLI, C .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (06) :1456-1467
[8]   Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome [J].
Cattrall, FR ;
Healy, DL .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2004, 18 (05) :803-812
[9]  
CRAIG JW, 1998, MOL BIOL DIABETES, V2, P343
[10]   Insulin-lowering agents in the management of polycystic ovary syndrome [J].
De Leo, V ;
la Marca, A ;
Petraglia, F .
ENDOCRINE REVIEWS, 2003, 24 (05) :633-667